Trials / Conditions / Advanced Ovarian Carcinoma

Advanced Ovarian Carcinoma

22 registered clinical trials studyying Advanced Ovarian Carcinoma — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent O NCT07144826	Ohio State University Comprehensive Cancer Center	EARLY_Phase 1
Active Not Recruiting	A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Brea NCT06630325	OHSU Knight Cancer Institute	Phase 2
Recruiting	REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors NCT06710548	Dana-Farber Cancer Institute	N/A
Recruiting	Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV O NCT06639074	Mayo Clinic	Phase 2
Recruiting	A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957	NiKang Therapeutics, Inc.	Phase 1
Terminated	A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921	NiKang Therapeutics, Inc.	Phase 1
Recruiting	At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860	Mayo Clinic	Phase 2
Withdrawn	ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer NCT05368506	OHSU Knight Cancer Institute	EARLY_Phase 1
Recruiting	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000	Northwestern University	Phase 2
Withdrawn	SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831	OHSU Knight Cancer Institute	EARLY_Phase 1
Recruiting	First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patien NCT05759923	Molecure S.A.	Phase 1
Unknown	Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression NCT05472857	Suzhou Immunofoco Biotechnology Co., Ltd	Phase 1
Recruiting	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484	National Cancer Institute (NCI)	Phase 1
Completed	Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients NCT05047926	Mayo Clinic	N/A
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534	National Cancer Institute (NCI)	Phase 1
Recruiting	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary NCT04575935	M.D. Anderson Cancer Center	Phase 3
Active Not Recruiting	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986	Roswell Park Cancer Institute	Phase 1 / Phase 2
Active Not Recruiting	Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary P NCT02659241	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer NCT02270372	Cascadian Therapeutics Inc.	Phase 1
Completed	Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer NCT00511992	University of Oklahoma	Phase 2